CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

A new drug called lepodisiran may offer hope to millions of people at risk of heart attacks and strokes by targeting a little ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.